The United States received a second vaccine against coronavirus for mass vaccination. The use of the vaccine Moderna will start next week, it requires more than a standard storage conditions than vaccines Pfizer. The US government has said that the government will purchase an additional 100 million doses of vaccine Moderna.
Stock Moderna (MRNA), an increase of 636% since the beginning of the year on Thursday, rose more than 5% on news of the approval by the Committee of Management on sanitary inspection behind quality of foodstuff and medicines (FDA) for emergency use of the vaccine campaign against COVID-19.
Mass vaccination of Americans Moderna vaccine showed efficacy in preventing infection with the virus more than 94% will begin next week.
News Moderna influenced the us stock market in General, as the three key index on Thursday closed with strong gains, despite the negative report from the labor Department about the jump in new jobless claims for the second week in a row.
On Thursday, the S&P 500 rose 0.58%, Dow Jones up 0.49% and the Nasdaq Composite index by 0.84%.
FDA Advisory Committee on vaccines and related biological products voted to recommend that the emergency use of the vaccine Moderna (20-0 with one abstention).
On Monday, U.S. officials said they plan to ship the first batch of vaccines Moderna amount slightly less than 6 million doses immediately after the FDA will issue a permit. For a lasting immunity against coronavirus requires two doses of vaccine Moderna every four weeks.
Moderna received a government contract to supply 100 million vaccine doses amount to about $1.5 billion in August, a time when the company has conducted its testing. Last week the Federal government announced that it will purchase an additional 100 million doses of vaccine Moderna.
The vaccine, developed by Pfizer (PFE) and BioNtech (BNTX) has been approved by FDA a week ago, and its application began on Monday. Pfizer and BioNtech have contracts to supply 100 million doses of vaccine from COVID-19 in the amount of $1.9 billion with the Ministry of health and social services and the Ministry of defense.
Vaccine from Pfizer, also showed high efficiency of about 90%, but it requires storage at very low temperatures (-70℃ / -94 degrees Fahrenheit). According to reports, the company is negotiating with the US government at the expense of additional supplies.
Vaccine Moderna requires a more standard storage conditions in -15.56 °C.
At the same time, representatives of the FDA noted that vaccines Pfizer and Moderna is different from the licensed vaccines, as the data collected over a short period of testing (several months), is limited and the FDA will continue to monitor the process of vaccination and to form their recommendations for use.
Moderna vaccine is recommended for adults 18 years, but according to a member of the Commission, the FDA, abstention from voting, Michael kurilla, an expert on infectious diseases, National institutes of health, this age group was too broad and he does not have confidence in that, “for all these age groups, the benefits really outweigh the risk.”
Vaccine Moderna has been tested with about 30 000 participants, among whom were many representatives of different races, the results have demonstrated its safety and side effects were minor and usually lasted no longer than a week.
In the company Moderna stated that allocated pregnant women into a separate group of vaccinated, to track the effectiveness of the vaccine and to monitor their condition.
Health experts are asked to carefully consider the issue of vaccination to persons with chronic diseases and allergies.